Back to News
Jan 20, 2026 4:30 PM

Moderna–Merck Cancer Vaccine Shows Durable Benefit At 5 Years In High-Risk Melanoma

Moderna Inc. (NASDAQ:MRNA) and Merck & Co. Inc. (NYSE:MRK) on Tuesday shared median five-year follow-up data from the Phase 2b KEYNOTE-942/mRNA-4157-P201 study of mRNA-based individualized neoantigen therapy for a serious type of skin cancer.

The trial evaluated intismeran autogene (mRNA-4157 or V940) in combination with Merck’s Keytruda (pembrolizumab) for high-risk melanoma (stage III/IV) following complete resection (removed surgically).

In this pre-planned analysis, adjuvant treatment with intismeran autogene plus Keytruda demonstrates sustained and clinically meaningful improvement in the study’s primary endpoint, recurrence-free survival (RFS), reducing the risk of recurrence or death by 49% compared to Keytruda alone.

Moderna and Merck plan to present further data from follow-up analyses of primary and secondary endpoints at an ...